
Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million
The acquisition of the cancer treatment developer will enhance Sino's competitiveness and influence in oncology innovation, while also enabling potential future international transactions by leveraging LaNova's R&D capabilities, it added.
Sino added LaNova will become an indirect wholly owned subsidiary once the deal is completed, which is expected within 30 business days after regulatory conditions are met.
The firm had already bought a 4.91% stake in LaNova in November, opens new tab last year, paying around 142 million yuan ($19.80 million) at the time.
LaNova Medicines was founded in 2019, specialising in discovering and developing antibody-based cancer treatments, according to details mentioned on their website.
In November last year, Merck (MRK.N), opens new tab licensed an early-stage cancer drug LM-299 from LaNova in a deal worth up to $3.3 billion, taking over its development.
The drug candidate targets the PD-1 protein, which prevents the immune system from killing cancerous cells. It also curbs levels of VEGF protein, which can encourage tumor growth if found in excess.
($1 = 7.1729 Chinese yuan renminbi)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
13 minutes ago
- The Independent
Coats to buy US insole maker for brands including Adidas and Asics for £573m
London-listed footwear manufacturer Coats has agreed to buy a US company that makes premium shoe insoles for 770 million US dollars (£573 million). The company said acquiring OrthoLite means it is bringing together two 'global leaders' in the industry. OrthoLite makes open-cell foam insoles, designed to be a more comfortable and sustainable lining for shoes, for a swathe of shoemakers including Adidas, Nike, Converse and Asics. It has more than a third share of the market and supplies about 500 million pairs of insoles a year to around 550 brands. Coats, which is listed on London's FTSE 250 index, is a global specialist in thread manufacturing and making components for clothes and footwear. It said it had agreed to buy OrthoLite for an enterprise value of 770 million US dollars. The acquisition will be funded through a combination of new debt facilities with its existing lenders and by raising funds from issuing new shares to investors. Coats said it would benefit from expanding into the fast-growing premium insole market where there is a big overlap with its existing footwear customers. 'The combination of Coats and OrthoLite is fantastic news for both companies and for the footwear industry,' chief executive David Paja said. 'It brings together two global leaders in adjacent segments of the footwear components sector with a shared vision for innovation and sustainability and with unparalleled brands and customer relationships.'


Reuters
41 minutes ago
- Reuters
Fast lane
Follow on Apple or Spotify. Listen on the Reuters app. There's a race going on between the world's two largest auto makers, China and the United States, and the People's Republic is out in front. Host Carmel Crimmins talks innovation, protectionism, competition and who gets left behind with Reuters Greater China bureau chief Kevin Krolicki and global autos editor Brian Thevenot. Tortoise economies, and hot pot in cars to come. Read the special report on China's emerging dominance in the auto sector here. Sign up for the Reuters Econ World newsletter here. Sign up for the Reuters Auto File newsletter here For information on our privacy and data protection practices visit the Thomson Reuters Privacy Statement. You may also visit to opt out of targeted advertising. Further Listening China's price problem EV batteries China's 'Rotten-tail kids'


Reuters
44 minutes ago
- Reuters
UK's Coats Group to buy footwear insole maker OrthoLite for $770 million
July 16 (Reuters) - British thread manufacturer Coats Group (COA.L), opens new tab said on Wednesday it would buy U.S.-based footwear insole maker OrthoLite for $770 million, including debt.